Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. (DARE) on June 30, 2022. The report details the effective date of an exclusive license agreement previously entered into on March 31, 2022, with Organon International GmbH, an affiliate of Organon & Co.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt) for a reporting period. Instead, it outlines the financial terms of the license agreement for XACIATO (clindamycin phosphate vaginal gel, 2%) and future products:
- Upfront Payment: $10.0 million non-refundable and non-creditable payment from Organon, expected to be received in early Q3 2022.
- Royalties: Tiered double-digit royalties based on net sales of licensed products.
- Milestone Payments: Up to $182.5 million total, including:
- $2.5 million upon the first commercial sale in the U.S. (expected Q4 2022).
- Up to $180.0 million in tiered commercial sales and regulatory milestones.
- Interim Supply: Organon will purchase XACIATO from Dare at manufacturing costs plus a single-digit percentage markup until Organon assumes supply responsibilities.
Material Changes
The primary material change is the satisfaction of closing conditions, making the License Agreement fully effective as of June 30, 2022. This triggers the obligation for Organon to pay the $10.0 million upfront fee and initiates the royalty and milestone payment structures.
Outlook, Risks, and Contingencies
Management Commentary and Outlook:
- Dare expects the first commercial sale of XACIATO in the U.S. to occur during the fourth quarter of 2022.
- Dare remains responsible for regulatory interactions and interim product supply.
Risks and Contingencies:
- Dependence on Third Parties: Dare relies on Organon for commercialization and third parties for supply, lacking control over their efforts and resources.
- Payment Uncertainty: Actual payments may be significantly less than anticipated.
- Termination Rights: Organon may terminate the agreement in its entirety or on a country-by-country basis at its sole discretion after the first anniversary of the Effective Date with 120 days' notice.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to various risks.
Key Facts for Investor Verification
- Confirmation of the $10.0 million upfront payment receipt in Q3 2022.
- Timeline for the first commercial sale of XACIATO in the U.S. to trigger the $2.5 million milestone.
- Organon's commercialization strategy and sales performance for XACIATO.
- Any potential termination notices from Organon after the first anniversary of the agreement.
- Transition of supply responsibilities from Dare to Organon.